+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Blood & Plasma Components Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 183 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010964
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global blood and plasma components market is evolving rapidly, presenting both challenge and opportunity for senior stakeholders focused on advancing healthcare solutions and maintaining organizational resilience. This sector’s progress is driven by expanding clinical demands, innovation, and a growing need for reliable therapies across diverse patient populations.

Market Snapshot: Blood and Plasma Components Market

The blood and plasma components market experienced notable growth, increasing from USD 45.86 billion in 2024 to USD 48.62 billion in 2025. Projections indicate the market will reach USD 72.55 billion by 2032, with a compound annual growth rate (CAGR) of 5.90%. Expansion is fueled by broadening therapeutic use, continuous innovation in component processing, and rising demand for essential plasma-derived proteins. Wider clinical adoption, especially in emerging and advanced economies, combined with an industry-wide push for improved patient care, sustains an optimistic market outlook.

Scope & Segmentation

This comprehensive report offers decision-makers an in-depth analysis of the blood and plasma components market, highlighting opportunities and complexities across the global supply chain. The following key segments are covered:

  • Product Types: Platelets, red blood cells, white blood cells, and plasma proteins including albumin, coagulation factors such as Factor IX, Factor VIII, prothrombin complex concentrates, as well as immunoglobulins for both intravenous and subcutaneous use.
  • Applications: Diagnostic usage, research initiatives aimed at medical advances, and therapeutic interventions addressing various clinical needs.
  • End Users: Diagnostic laboratories, hospitals (spanning ambulatory surgical centers, government and private hospitals), and research institutions engaged in both clinical practice and innovation.
  • Distribution Channels: Hospital pharmacies prioritized for urgent care, online pharmacies supporting expanded access, and retail pharmacies ensuring routine availability.
  • Geographic Coverage: In-depth insights span the Americas (including the United States, Canada, and key Latin American countries), Europe (covering the United Kingdom, Germany, France, and significant regional markets), the Middle East and Africa (with markets such as the UAE, Saudi Arabia, and South Africa), and Asia-Pacific (notably China, India, Japan, and several rapidly developing markets).
  • Company Profiles: Industry leaders such as CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Biotest AG, KEDRION S.p.A., Shanghai RAAS Blood Products Co., Ltd, Bio Products Laboratory Limited, LFB S.A., and Sanquin Blood Supply Foundation.

Key Takeaways

  • Technological innovation in blood fractionation and purification is enhancing the efficiency and safety of plasma-derived therapeutics, helping organizations respond to evolving therapeutic requirements.
  • The shift towards automated systems and digital monitoring platforms is improving traceability while strengthening the integrity of production and distribution processes within the market.
  • Consolidation through mergers and acquisitions is reshaping the competitive landscape, leading to diversified product portfolios and stronger security over supply chains.
  • Rising interest in personalized medicine is increasing demand for advanced plasma-based treatments, notably immunoglobulin therapies that address complex autoimmune and neurological diseases.
  • Compliance with emerging regulations is driving sustained investment in quality control and workforce training, further elevating standards and increasing barriers to entry.
  • Distinct regional dynamics continue to influence growth potential, with mature infrastructure supporting North America, varied regulatory responses in Europe and the Middle East & Africa, and intensified healthcare modernization accelerating expansion in Asia-Pacific.

Tariff Impact: Navigating Regulatory and Economic Shifts

Ongoing regulatory measures, including proposed tariffs in the United States, are creating new cost dynamics and prompting organizations to re-align supply chain strategies. Industry stakeholders are responding by investing in domestic manufacturing capabilities and establishing long-term procurement partnerships to ensure continuous access to blood and plasma-derived products. These adaptive strategies help minimize supply disruptions and protect patient care delivery amid shifting policy environments.

Methodology & Data Sources

This report synthesizes primary insights from clinician, procurement, and laboratory manager interviews with in-depth secondary research, including regulatory documentation, clinical trial outcomes, and corporate reports. Validation was achieved through targeted industry surveys and review by interdisciplinary experts, ensuring comprehensive and relevant findings.

Why This Report Matters

  • Empowers executive teams to manage regulatory and tariff-driven risks with targeted, actionable insights.
  • Provides guidance for investing in automation and digital initiatives that boost traceability, adaptability, and market positioning across all geographic regions.
  • Supports timely identification of growth areas within clinical and diagnostic segments, optimizing strategic direction and resource allocation.

Conclusion

Leveraging data-driven strategies remains crucial for navigating the evolving clinical and regulatory environment of the blood and plasma components market. Informed decision-making strengthens both business and clinical outcomes, positioning organizations at the forefront of healthcare advancement.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Increasing demand for recombinant albumin alternatives driven by supply constraints in human plasma
5.2. Development of hyperimmunoglobulin therapies targeting emerging infectious diseases to bolster passive immunity
5.3. Expansion of fractionation capacity in Asia Pacific to meet rising demand for immunoglobulin therapies
5.4. Adoption of pathogen reduction technologies in blood processing to enhance transfusion safety standards
5.5. Growing investment in continuous flow plasmapheresis devices to improve donor throughput and efficiency
5.6. Rising corporate consolidation among plasma fractionators reshaping competitive dynamics and pricing
5.7. Shift towards decentralized blood banking models using point-of-care testing to expand rural accessibility
5.8. Integration of artificial intelligence for predictive donor screening and supply chain optimization
5.9. Emergence of recombinant coagulation factors reducing dependency on plasma-derived concentrates
5.10. Implementation of novel viral inactivation methods to address safety concerns in plasma products
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Blood & Plasma Components Market, by Product Type
8.1. Plasma Proteins
8.1.1. Albumin
8.1.2. Coagulation Factors
8.1.2.1. Factor IX
8.1.2.2. Factor VIII
8.1.2.3. Prothrombin Complex Concentrates
8.1.3. Immunoglobulins
8.1.3.1. Intravenous Immunoglobulin
8.1.3.2. Subcutaneous Immunoglobulin
8.2. Platelets
8.3. Red Blood Cells
8.4. White Blood Cells
9. Blood & Plasma Components Market, by Application
9.1. Diagnostic
9.2. Research
9.3. Therapeutic
10. Blood & Plasma Components Market, by End User
10.1. Diagnostic Laboratories
10.2. Hospitals
10.2.1. Ambulatory Surgical Centers
10.2.2. Government Hospitals
10.2.3. Private Hospitals
10.3. Research Institutions
11. Blood & Plasma Components Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Blood & Plasma Components Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Blood & Plasma Components Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Blood & Plasma Components Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. CSL Limited
15.3.2. Grifols, S.A.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. Octapharma AG
15.3.5. Biotest AG
15.3.6. KEDRION S.p.A.
15.3.7. Shanghai RAAS Blood Products Co., Ltd
15.3.8. Bio Products Laboratory Limited
15.3.9. LFB S.A.
15.3.10. Sanquin Blood Supply Foundation

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Blood & Plasma Components market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • KEDRION S.p.A.
  • Shanghai RAAS Blood Products Co., Ltd
  • Bio Products Laboratory Limited
  • LFB S.A.
  • Sanquin Blood Supply Foundation

Table Information